Susanna Naggie, MD

Associate Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, 6th Floor - 6410, Durham, NC 27701
Phone (919) 684-2584
Email address susanna.naggie@duke.edu

Dr. Susanna Naggie completed her medical education at Johns Hopkins School of Medicine and her internal medicine training at Duke University Medical Center (DUMC), where she also served as a Chief Resident in Internal Medicine.  She completed her Infectious Diseases (ID) fellowship training at Duke and then joined the faculty in the Division of ID. She is an Associate Professor of Medicine with Tenure and currently holds joint appointments at the Duke Clinical Research Institute (DCRI, Director of ID Research), and at the Durham Veterans Affairs Medical Center (DVAMC). Dr. Naggie has dedicated her academic career to the care of patients with HIV and viral hepatitis, with a research program focused on understanding the mechanisms of accelerated liver fibrogenesis in this population and the extrahepatic health outcomes attributed to HCV in persons with HIV infection. In addition to her investigator-initiated research program, Dr. Naggie is also involved in multiple clinical trials and clinical registries with a particular focus on HIV and liver disease. She is the prior co-Chair of the AASLD/IDSA HCV Guidance Committee and is currently Chair of the AIDS Clinical Trials Group Viral Hepatitis Transformative Science Group Committee and a member of the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV and the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline Committee. For the past two years Dr. Naggie has served as the Medical Director of the Duke Department of Medicine Clinical Research Unit.

Education and Training

  • Fellow in Infectious Diseases, Medicine, Duke University, 2007 - 2009
  • Chief Medical Resident - VAMC, Medicine, Duke University, 2006 - 2007
  • Medical Resident, Medicine, Duke University, 2002 - 2005
  • M.D., Johns Hopkins University, 2002

Publications

Suhy, David, Keyur Patel, Georgina Kilfoil, David L. Wyles, Susanna Naggie, Eric Lawitz, Stephen Bradley, and Per Lindell. “Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi) delivered as a single administration for the treatment of subjects with chronic hepatitis C virus (HCV).” Hepatology 62, no. 6 (December 1, 2015): 1386A-1386A.

Scholars@Duke

Muir, Andrew J., and Susanna Naggie. “Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?.” Clin Gastroenterol Hepatol 13, no. 12 (November 2015): 2166–72. https://doi.org/10.1016/j.cgh.2015.07.015.

PMID
26192145
Full Text

Rabatin, Abigail, Mohamed Hashem, Mary L. Townsend, William E. Bryan, Cynthia A. Moylan, Steve S. Choi, and Susanna Naggie. “Treatment Outcomes of Veterans with Decompensated Cirrhosis Receiving All Oral Direct Acting Antiviral Hepatitis C Therapy.” In Hepatology, 62:773A-773A. WILEY-BLACKWELL, 2015.

Scholars@Duke

Rockstroh, J., C. Cooper, S. Naggie, M. Saag, J. Yang, L. Stamm, P. Pang, J. McHutchison, D. Dieterich, and M. Sulkowski. “A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection: the Phase 3 ION-4 study.” Journal of Viral Hepatitis 22 (September 1, 2015): 24–24.

Scholars@Duke

AASLD/IDSA HCV Guidance Panel, Cathrine. “Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus..” Hepatology 62, no. 3 (September 2015): 932–54. https://doi.org/10.1002/hep.27950.

PMID
26111063
Full Text

Naggie, Susanna, Curtis Cooper, Michael Saag, Kimberly Workowski, Peter Ruane, William J. Towner, Kristen Marks, et al. “Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1..” N Engl J Med 373, no. 8 (August 20, 2015): 705–13. https://doi.org/10.1056/NEJMoa1501315.

PMID
26196665
Full Text

Naggie, Susanna, Curtis Cooper, Michael Saag, Kimberly Workowski, Peter Ruane, William J. Towner, Kristen Marks, et al. “Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.” New England Journal of Medicine 373, no. 8 (August 20, 2015): 705–13. https://doi.org/10.1056/NEJMoa1501315.

Full Text

Younossi, Zobair M., Maria Stepanova, Mark Sulkowski, Susanna Naggie, Massimo Puoti, Chloe Orkin, and Sharon L. Hunt. “Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes..” J Infect Dis 212, no. 3 (August 1, 2015): 367–77. https://doi.org/10.1093/infdis/jiv005.

PMID
25583164
Full Text

Naggie, Susanna, Curtis Cooper, Michael Saag, Jenny C. Yang, Luisa M. Stamm, Philip S. Pang, John G. McHutchison, Douglas Dieterich, and Mark S. Sulkowski. “Ledipasvir/sofosbuvir for 12 weeks in patients co-infected with HCV and HIV-1.” Journal of the International Aids Society 18 (July 1, 2015). https://doi.org/10.7448/IAS.18.5.20362.

Full Text

Pages